key: cord-0765031-jmrgmkcw authors: Stephan, Dominique; Cordeanu, Mihaela; Mirea, Corina; Salier, Gabrielle; Heitz, Marie; Lambach, Hélène; Pianezze, Marion; Frantz, Anne-Sophie title: Maladie veineuse thrombo-embolique et COVID-19 date: 2020-08-12 journal: nan DOI: 10.1016/j.lpmfor.2020.08.005 sha: 3c5178cc0b9dcf19dc393f1afe7fa435c58cd41a doc_id: 765031 cord_uid: jmrgmkcw nan COVID-19 is associated with higher risk of venous thrombosis but also arterial and micovascular Marked inflammation in severe forms is associated with an increase in D-dimer level which could be an indicator of the thrombotic risk. A confirmed or suspected COVID-19 patient with clinical signs suggesting a venous thrombotic event should be hospitalized for diagnostic assessment Performing a venous doppler ultrasound in a confirmed or suspected COVID-19 patient requires operator protection and disinfection of the ultrasound equipment after the examination. Computed tomography pulmonary angiogram (CTPA) is the examination of choice in COVID-19 patients with suspected pulmonary embolism Thromboprophylaxis prophylactic anticoagulation is suggested in all hospitalized COVID-19 patients High-dose thromboprophylaxis proposed in COVID-19 patients with additional risk factor for venous thrombosis and in particular obese. Extension of prophylactic anticoagulant therapy after hospital discharge is proposed for COVID-19 patients adding risk factors for venous thrombosis Therapeutic anticoagulation relies low molecular weight heparin, direct oral anticoagulants or antivitamin K for a durantion of three to six months. Particular attention must be paid to the risk of drug interactions between anticoagulants and pharmacological treatments of COVID-19 infection (eg antiretroviral or anti-cytokins agents) J o u r n a l P r e -p r o o f 5 patients COVID chinois hospitalisés, 40% des malades avait un score de Padoue supérieur ou égal à 4, ce qui correspondait à un risque thrombotique veineux élevé [6] . Seulement 7% de la cohorte recevait une prophylaxie anti-thrombotique. Enfin, dans cette cohorte, le risque élevé de MVTE était également associé à un risque de saignement majoré soulignant le bénéficie mais également le risque du traitement anticoagulant chez ces patients [6] . Il est variable selon le statut du patient. Chez les patients COVID positifs ou COVID suspects, l'équipement de protection doit être maximal dans la mesure de la dotation avec China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China COVID-19 Complicated by Acute Pulmonary Embolism Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 Lancet Haematology Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Coagulopathy and Antip.hospholipid Antibodies in Patients with Covid-19 International consensus statement on preliminary classification criteria for definite antiphospholipidsyndrome (APS) Antihypertensive drugs and risk of COVID-19? www.thelancet.com/respiratory Ultrasound for Lower Extremity Deep Venous Thrombosis Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalise avec covid-19 et surveillance de l'hémostase propositions du GIHP et du GFHT sur la survenue d'événements thrombo-emboliques veineux chez les patients atteints de COVID-19 hospitalisés : essai multicentrique randomisé en ouvert COVI-DOSE A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients Efficacité d'une dose de 10 mg de rivaroxaban versus pas de traitement chez des malades COVID-19 avec au moins l'un des critères suivants : âge >75 ans, antécédents de MVTE ou de cancer, D-dimères > 1000 µg/L, insuffisance cardiaque ou respiratoire, sur la survenue d'événements thrombo-emboliques veineux chez les patients atteints de COVID-19, essai multicentrique, randomisé en ouvert